Longitudinal FGF23 Trajectories and Mortality in Patients with CKD

Journal of the American Society of Nephrology

Volumn 29, Issue 2, 2018, Pages 579-590

  Isakova, Tamara ^a,o   Cai, Xuan ^a   Lee, Jungwha ^a   Xie, Dawei ^b   Wang, Xue ^b   Mehta, Rupal ^a   Allen, Norrina B ^a   Scialla, Julia J ^c,d   Pencina, Michael J ^d   Anderson, Amanda H ^b   Talierco, John ^e   Chen, Jing ^f   Fischer, Michael J ^g,h   Steigerwalt, Susan P ⁱ   Leonard, Mary B ^j,k   Hsu, Chi yuan ^l   De Boer, Ian H ^m   Kusek, John W ⁿ   Feldman, Harold I ^b   Dr, Myles Wolf ^c,d,o  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ILLINOIS   (United States)

^h HINES VA HOSPITAL   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^j STANFORD UNIVERSITY   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁿ NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^o NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHATE; SERUM ALBUMIN; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; ILLNESS TRAJECTORY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; EPIDEMIOLOGY; MULTICENTER STUDY; UNITED STATES;

AGED; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

EID: 85041467059     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2017070772     Document Type: Article

References (37)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
2. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
3. Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB: Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 9: 344-353, 2014
4. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
5. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
6. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
7. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011
8. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I: Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22: 956-966, 2011
9. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
10. Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C: Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22: 1020-1032, 2015
11. Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenstädt HJ, Meersch M, Unruh M, Zarbock A: FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 126: 962-974, 2016
12. Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, Di Marco GS, Brand M, Wolf M, Faul C: Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 90: 985-996, 2016
13. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25: 349-360, 2014
14. Mehta R, Cai X, Lee J, Scialla JJ, Bansal N, Sondheimer JH, Chen J, Hamm LL, Ricardo AC, Navaneethan SD, Deo R, Rahman M, Feldman HI, Go AS, Isakova T, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the Chronic Renal Insufficiency Cohort Study. JAMA Cardiol 1: 548-556, 2016
15. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK: Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol 27: 227-237, 2016
16. Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D: FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem 289: 9795-9810, 2014
17. Mehta R, Cai X, Hodakowski A, Lee J, Leonard M, Ricardo A, Chen J, Hamm L, Sondheimer J, Dobre M, David V, Yang W, Go A, Kusek JW, Feldman H, Wolf M, Isakova T; CRIC Study Investigators: Fibroblast growth factor 23 and anemia in the Chronic Renal Insufficiency Cohort Study [published online ahead of print August 7, 2017]. Clin J Am Soc Nephrol doi:10.2215/CJN.03950417
18. Jones B, Nagin D, Roeder K: A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res 29: 374-393, 2001
19. Nagin DS, Odgers CL: Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 6: 109-138, 2010
20. Nagin DS, Odgers CL: Group-based trajectory modeling (nearly) two decades later. J Quant Criminol 26: 445-453, 2010
21. Gill TM, Gahbauer EA, Han L, Allore HG: Trajectories of disability in the last year of life. N Engl J Med 362: 1173-1180, 2010
22. Allen NB, Siddique J, Wilkins JT, Shay C, Lewis CE, Goff DC, Jacobs DR Jr., Liu K, Lloyd-Jones D: Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA 311: 490-497, 2014
23. Song M, Hu FB, Wu K, Must A, Chan AT, Willett WC, Giovannucci EL: Trajectory of body shape in early and middle life and all cause and cause specific mortality: Results from two prospective US cohort studies. BMJ 353: i2195, 2016
24. Bouma-de Krijger A, Bots ML, Vervloet MG, Blankestijn PJ, Ter Wee PW, van Zuilen AD, Wetzels JF: Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease. Nephrol Dial Transplant 29: 88-97, 2014
25. David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, Wolf M: Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89: 135-146, 2016
26. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5: 286-291, 2010
27. Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, Xie H, Wahl P, Schiavenato E, Dosch A, Gutiérrez OM, Diego J, Lenz O, Contreras G, Mendez A, Weiner RB, Wolf M: Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 8: 1009-1018, 2013
28. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23: 1407-1415, 2012
29. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: The Chronic Renal Insufficiency Cohort (CRIC) study: Design and methods. J Am Soc Nephrol 14[Suppl 2]: S148-S153, 2003
30. Wacholder S, Gail M, Pee D: Selecting an efficient design for assessing exposure-disease relationships in an assembled cohort. Biometrics 47: 63-76, 1991
31. Prentice RL: A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73: 1-11, 1986
32. Barlow WE, Ichikawa L, Rosner D, Izumi S: Analysis of case-cohort designs. J Clin Epidemiol 52: 1165-1172, 1999
33. Isakova T, Xie H, Barchi-Chung A, Vargas G, Sowden N, Houston J, Wahl P, Lundquist A, Epstein M, Smith K, Contreras G, Ortega L, Lenz O, Briones P, Egbert P, Ikizler TA, Jueppner H, Wolf M: Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 6: 2688-2695, 2011
34. Raghunathan TE, Solenberger PW, Van Hoewyk J: IVEware: Imputation and Variance Estimation Software, Ann Arbor, MI, University of Michigan, Institute for Social Research, Survey Research Center, 2000
35. Raghunathan TE, Lepkowski JM, Van Hoewyk J: A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 27: 85-95, 2001
36. Rubin DB: Multiple Imputation for Nonresponse in Surveys, New York, John Wiley and Sons, 2004
37. Gutiérrez OM, Wolf M, Taylor EN: Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 6: 2871-2878, 2011